Financial Ratios

BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.

NSE : NABSE : 524663ISIN CODE : INE994B01014Industry : Pharmaceuticals & DrugsHouse : PSU
BSE33.313.69 (+12.46 %)
PREV CLOSE ( ) 29.62
OPEN PRICE ( ) 29.85
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 394751
TODAY'S LOW / HIGH ( )29.69 33.70
52 WK LOW / HIGH ( ) 20.543.89
NSE
This Company is not listed in NSE
Select year
ParticularsMar2023Mar2022Mar2021Mar2020Mar2019
Operational & Financial Ratios
   Earnings Per Share (Rs)-3.85-2.03-4.19-2.36-1.34
   CEPS(Rs)-3.81-1.98-4.14-2.31-1.28
   DPS(Rs)0.000.000.000.000.00
   Book NAV/Share(Rs)-5.33-1.480.554.747.10
   Tax Rate(%)25.289.6425.1828.1121.43
Margin Ratios
   Core EBITDA Margin(%)-36.02-6.34-24.45-15.56-11.14
   EBIT Margin(%)-34.09-5.21-22.76-14.14-6.42
   Pre Tax Margin(%)-49.92-12.36-28.37-21.25-8.82
   PAT Margin (%)-37.30-11.17-21.23-15.28-6.93
   Cash Profit Margin (%)-36.85-10.90-20.95-14.92-6.60
Performance Ratios
   ROA(%)-9.41-6.35-18.41-8.97-7.22
   ROE(%)0.000.00-158.64-39.93-17.00
   ROCE(%)-25.63-8.08-73.05-21.87-10.70
   Asset Turnover(x)0.250.570.870.591.04
   Sales/Fixed Asset(x)0.280.771.872.5914.05
   Working Capital/Sales(x)-0.77-2.19-2.83-8.698.15
Efficiency Ratios
   Fixed Capital/Sales(x)3.531.300.540.390.07
   Receivable days61.402.6637.69247.35194.00
   Inventory Days154.12115.80139.46180.6535.26
   Payable days8.9047.94131.08286.05115.09
Valuation Parameters
   PER(x)0.000.000.000.000.00
   PCE(x)-5.83-14.21-10.99-2.52-6.02
   Price/Book(x)-4.16-18.9883.211.231.08
   Yield(%)0.000.000.000.000.00
   EV/Net Sales(x)3.532.382.500.240.69
   EV/Core EBITDA(x)-10.48-48.10-11.12-1.74-11.29
   EV/EBIT(x)-10.34-45.60-10.98-1.70-10.71
   EV/CE(x)0.970.972.540.140.50
   M Cap / Sales2.151.552.300.380.40
Growth Ratio
   Net Sales Growth(%)-43.09-8.1427.68-20.10140.37
   Core EBITDA Growth(%)-287.7079.82-108.19-80.9022.05
   EBIT Growth(%)-272.4078.97-105.48-76.0122.72
   PAT Growth(%)-90.0851.67-77.38-76.27-35.93
   EPS Growth(%)-90.0851.67-77.38-76.27-35.93
Financial Stability Ratios
   Total Debt/Equity(x)-3.05-12.1811.560.151.05
   Current Ratio(x)0.380.650.530.921.12
   Quick Ratio(x)0.370.290.320.410.95
   Interest Cover(x)-2.15-0.73-4.06-1.99-2.68
   Total Debt/Mcap(x)0.730.640.140.120.97

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.